Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer

NCT01936363 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT01936363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01936363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer
Lead sponsor
EMD Serono
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
November 30, 2017
Enrollment
65 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer